CYBN Company Profile and Key Details

CYBN has shown sold momentum, gaining 13.97% over the past week and 19.67% over the past quarter, though year-to-date performance is down -18.59%. Short-term trend indicators are bullishly aligned (SMA20 16.17%, SMA50 15.2%, SMA200 3.88%). The stock’s 14-day RSI is 67.39 (firm momentum), while the ATR of 0.4 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -33.08% below its high and over 49.27% above its low. Average 10-day trading volume of 805.73 thousand shares is in line with the 3-month average of 831.97 thousand, indicating normal recent market interest.

Cybin Inc. generated EPS of -$3.89 over the past year. Five-year average earnings growth is -232.48%. Wall Street analysts project EPS growth of 16.8% annually over the next five years. The latest quarter delivered EPS of -$1.39. The next quarter is forecast at -$0.58. Next year's EPS is expected at $22.98. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $190.00 to $35.00. The high target offers 2546.24% upside. The low target suggests 387.47% downside. The mean target is $83.25. This offers 1059.47% upside. Cybin Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by 87.84%. The prior quarter beat by 115.69%. Over the last six quarters, Apple has recorded several small beats. These include -50.0% in August 08, 2024.

Cybin Inc. trades at a P/E ratio of -2.41, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.73 suggesting the stock is closer to book value. The P/FCF stands at -4.32, also below market averages.

Our AI price prediction model suggests that Cybin Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.69%, with price expected at $7.66 by January 02, 2026, within a range of $7.31 to $8.01 3-Month Outlook: Projected fall of -44.71%, reaching $3.97 by March 19, 2026, with a range of $3.69 to $4.27. 1-Year Outlook: Projected gain of 23.12%, with price at $8.84 by December 18, 2026, within a range of $0.00 to $13.16.

Cybin Inc. (AMEX:CYBN) shares are down -18.59% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cybin Inc. trading at a premium to the broader market with a P/E of -2.41. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $48.78, suggesting 579.39% upside. Our AI forecast model points to short-term strength (6.69% over two weeks), a medium-term fall (-44.71% over three months), and a longer-term gain (23.12% over one year), with expected trading ranges indicating moderate volatility.

Cybin Inc. (AMEX:CYBN) closed at $7.10 USD, losing -$0.08 (-1.11%) from the previous close of $7.18. The stock is currently mid-range between its 52-week high and low $4.81 and $10.73. With a market capitalization of about $354.16 million, Cybin Inc. is classified as a small-cap and shows market-like volatility (beta ~1.09). Key stats such as the average daily volume over the past year has been around 843.56 thousand shares, volume is running light vs its 52-week average. Headquartered in Toronto, ON, Cybin Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Eric So, the company employs approximately 50 people and listed since September 13, 2019. Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics.

Cybin Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.53. This means the shares are trading above this model’s fair value.